肝细胞肝癌中Notch1蛋白和ADAM17蛋白的表达及其临床意义

目的探讨Notch1蛋白和ADAM 17蛋白在肝细胞肝癌(HCC)中的表达及临床病理学意义。方法采用免疫组织化学ENVISION法检测Notch1和ADAM 17蛋白在78例HCC组织和10例癌旁正常肝组织标本中的表达,并分析其与临床病理参数的相关性。结果 HCC组织Notch1的表达率为66.67%(52/78),明显高于癌旁组织的20.00(2/10)(P<0.05);HCC组ADAM17表达率为87.18%(68/78),明显高于癌旁组织的10.00(1/10)(P<0.01)。Notch1和ADAM17阳性表达与HCC大小、TNM分期、有无转移及生存时间相关。结论 Notch1和ADAM17蛋白可能协同参与了HCC的发生发展和转移,并可以作HCC预后判断的指标。

Expressions and significance of Notch1 and ADAM17 in hepatocellular carcinoma

Objective To investigate the expressions of Notch1 and ADAM17 in hepatocellular carcinoma(HCC) and the relationship between their expressions and clinicopathological features.Methods The expressions of Notch1 and ADAM17 in HCC tissues of 78 cases(group A) and tumor-adjacent tissues of 10 HCC cases were detected by ENVISION immunohistochemistry method.The relationship between the expressions of them and clinicopathological criteria was analyzed.ResultsThe expression of Notch1 was higher in group A than that in group B(66.67% vs.20.00%)(P<0.05).The expression of ADAM17 was higher in group A than that in group B(87.18% vs.10.00%)(P<0.01).The expressions of ADAM17 and Notch1 were correlated with tumor size,TNM staging,metastasis and survival index.Conclusion The overexpressions of ADAM17 and Notch1 are closely related with HCC development,metastasis and survival time.Combined detection of ADAM17 and Notch1 in HCC may be taken as an indicator for predicting the prognosis of patients with HCC.